Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

CAS  PubMed  Google Scholar 

Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, et al. Understanding breast cancer complexity to improve patient outcomes: the St Gallen international consensus conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol. 2023;34:970–86.

CAS  PubMed  Google Scholar 

Sleightholm R, Neilsen BK, Elkhatib S, Flores L, Dukkipati S, Zhao R, et al. Percentage of hormone receptor positivity in breast cancer provides prognostic value: a single-institute study. J Clin Med Res. 2021;13:9–19.

PubMed  PubMed Central  Google Scholar 

Makhlouf S, Quinn C, Toss M, Alsaleem M, Atallah NM, Ibrahim A, et al. Quantitative expression of oestrogen receptor in breast cancer: clinical and molecular significance. Eur J Cancer. 2024;197:113473.

CAS  PubMed  Google Scholar 

Ma H, Lu Y, Marchbanks PA, Folger SG, Strom BL, McDonald JA, et al. Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res. 2013;15:R90.

PubMed  PubMed Central  Google Scholar 

Li AQ, Zhou SL, Li M, Xu Y, Shui RH, Yu BH, et al. Clinicopathologic characteristics of oestrogen receptor-positive/progesterone receptor-Negative/Her2-Negative breast cancer according to a novel definition of negative progesterone receptor status: a large population-based study from China. PLoS ONE. 2015;10:e0125067.

PubMed  PubMed Central  Google Scholar 

Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017;28:2420–8.

CAS  PubMed  PubMed Central  Google Scholar 

Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol. 2014;25:1004–11.

CAS  PubMed  PubMed Central  Google Scholar 

Yoon KH, Park Y, Kang E, Kim EK, Kim JH, Kim SH, et al. Effect of estrogen receptor expression level and hormonal therapy on prognosis of early breast cancer. Cancer Res Treat. 2022;54:1081–90.

CAS  PubMed  Google Scholar 

Onagi H, Horimoto Y, Okano S, Sasa K, Ishizuka Y, Ichida M, et al. Clinicopathological characteristics of Japanese patients with breast cancer and MET exon 14 skipping alterations. Histopathol. 2024;86(5):750–61.

Google Scholar 

Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T. Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) pathology section. Jpn J Clin Oncol. 1998;28:486–91.

CAS  PubMed  Google Scholar 

Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38:1346–66.

PubMed  Google Scholar 

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.

PubMed  PubMed Central  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105–22.

CAS  PubMed  Google Scholar 

Hill DA, Barry M, Wiggins C, Nibbe A, Royce M, Prossnitz E, et al. Estrogen receptor quantitative measures and breast cancer survival. Breast Cancer Res Treat. 2017;166:855–64.

CAS  PubMed  PubMed Central  Google Scholar 

Matsumoto N, Wanifuchi-Endo Y, Fujita T, Asano T, Terada M, Nozawa K, et al. Prognosis, clinicopathological characteristics, and treatment patterns of patients with ER-intermediate-positive breast cancer undergoing long-term follow-up. ESMO Open. 2025;10:104508.

CAS  PubMed  PubMed Central  Google Scholar 

Voorwerk L, Sanders J, Keusters MS, Balduzzi S, Cornelissen S, Duijst M, et al. Immune landscape of breast tumors with low and intermediate estrogen receptor expression. NPJ Breast Cancer. 2023;9:39.

CAS  PubMed  PubMed Central  Google Scholar 

Makhlouf S, Althobiti M, Toss M, Muftah AA, Mongan NP, Lee AHS, et al. The clinical and biological significance of estrogen receptor-low positive breast cancer. Mod Pathol. 2023;36:100284.

CAS  PubMed  Google Scholar